Skip to content
Shorla Oncology: A Leader in Innovative Oncology Solutions
  • About Us
    • Executive Team
    • Leadership Team
    • Board of Directors
    • Advisory Team
  • Products
    • TEPYLUTE
    • IMKELDI
    • JYLAMVO
    • Nelarabine Injection
  • Pipeline
  • News
    • Company Updates
    • Media
  • Careers
  • Contact

Media

SH-110 receives FDA orphan drug designation for the treatment of Glioma

July 22nd 2025

Read More

Cure Today Logo

FDA Grants Orphan Status to Liquid Glioma Treatment SH-110

July 18th 2025

Read More

Oncology Live Logo

FDA Grants Orphan Drug Designation to SH-110 for Oral Suspension in Glioma

July 17th 2025July 16th 2025

Read More

AMERICAN PHARMACEUTICAL REVIEW LOGO

Oral Liquid for Brain Cancer Gets FDA Fast Track Designation

July 17th 2025July 16th 2025

Read More

FDA Grants Orphan Drug Designation to SH-110, a Liquid Glioma Therapy

July 17th 2025July 16th 2025

Read More

YPO Features Sharon

Sharon Cunningham Featured by YPO for Driving Innovation in Oncology

July 17th 2025June 9th 2025

Read More

Cancer Network Logo

FDA Approves Multidose Thiotepa Vial for Breast and Ovarian Cancers

May 16th 2025April 30th 2025

Read More

Cancer Therapy Advisor logo

Tepylute, a Ready-to-Dilute Formulation of Thiotepa, Now Available

May 16th 2025April 30th 2025

Read More

Rare Cancer News Logo

Tepylute for breast, ovarian cancer launched in US

May 16th 2025April 30th 2025

Read More

Older posts
Page1 Page2 … Page7
Logo

IRELAND HQ:
Questum Acceleration Center,
Ballingarrane Science & Technology Park,
Clonmel, Co. Tipperary,
E91 V329, Ireland

Shorla Pharma Ltd trading as Shorla Oncology®

All trademarks are the property of their respective owners.

US OFFICE:
245 Main St.,
2nd floor,
Cambridge,
MA 02142, USA

SITEMAP

PRIVACY POLICY

CALIFORNIA COMPLIANCE PROGRAM DECLARATION

Company number: 618033
©SHORLA ONCOLOGY® 2025

© 2025 Shorla Oncology: A Leader in Innovative Oncology Solutions • Built with GeneratePress
  • About Us
    • Executive Team
    • Leadership Team
    • Board of Directors
    • Advisory Team
  • Products
    • TEPYLUTE
    • IMKELDI
    • JYLAMVO
    • Nelarabine Injection
  • Pipeline
  • News
    • Company Updates
    • Media
  • Careers
  • Contact

Now approved for use in Pediatrics

  • Treatment of pediatric patients with polyarticular juvenile idiopathic arthritis (pJIA).
  • Treatment of pediatric patients with acute lymphoblastic leukemia (ALL) as part of a combination chemotherapy maintenance regimen.

Please click here for the full Prescribing information, including Boxed Warning regarding embryo-fetal toxicity, hypersensitivity reactions, and severe adverse reactions.